If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-20. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
where the ion AB+ collides with the neutral species M and subsequently breaks apart. The details of this process are described by collision theory. Due to different instrumental configuration, two main different types of CID are possible: (i) beam-type (in which precursor ions are fragmented on-the-flight) and (ii) ion trap-type (in which precursor ions are first trapped, and then fragmented). A third and more recent type of CID fragmentation is higher-energy collisional dissociation (HCD). HCD is a CID technique specific to orbitrap mass spectrometers in which fragmentation takes place external to the ion trap, it happens in the HCD cell (in some instruments named "ion routing multipole"). HCD is a trap-type fragmentation that has been shown to have beam-type characteristics. Freely available large scale high resolution tandem mass spectrometry databases exist (e.g. METLIN with 960,000 molecular standards each with experimental CID MS/MS data), and are typically used to facilitate small molecule identification.
The Islamabad Talks, also known as the Islamabad Peace Talks, were held in Islamabad, Pakistan, on 11 and 12 April 2026. Aimed at stabilizing the 2026 Iran war ceasefire and negotiating a potential resolution to the war, the talks were moderated by Pakistan, which played a central role in brokering the ceasefire and facilitating the talks. The 300-member U.S. negotiating team was led by Vice President JD Vance, alongside special envoys Steve Witkoff and Jared Kushner; while the 70-member Iranian team was led by parliamentary speaker Mohammad Bagher Ghalibaf, alongside foreign minister Abbas Araghchi. The Pakistani mediating team was led by prime minister Shehbaz Sharif, field marshal Asim Munir, and deputy prime minister and foreign minister Ishaq Dar. The talks lasted 21 hours between 11 and 12 April 2026, and consisted of three rounds with the first one being indirect and the second and third ones being direct. The day of the meeting, Trump told reporters that he did not care about whether an agreement would come out of the talks. The teams were reportedly able to agree on the main points of the 10-points ceasefire, with the exception of the issues regarding the Strait of Hormuz and the Iranian nuclear program. The talks ended with no agreement reached, and no memorandum of understanding (MoU) being issued. Following the failure of the talks, U.S. president Donald Trump imposed a naval blockade on Iran on 13 April, interdicting any ships entering or departing Iranian ports.
The Gaultheria species share the common characteristic of producing oil of wintergreen. Wintergreen oil is a pale yellow or pinkish fluid liquid that is strongly minty aromatic described as "fresh, sweet, and characteristically wintergreen" (components: methyl salicylate (about 98%), α-pinene, myrcene, delta-3-carene, limonene, 3,7-guaiadiene, and delta-cadinene) that gives such plants a distinctive "medicinal" smell whenever bruised. Salicylate sensitivity is a common adverse reaction to the methyl salicylate in oil of wintergreen; it can produce allergy-like symptoms or asthma. Wintergreen essential oil is usually obtained by steam distillation of the leaves of the plant following maceration in warm water. Methyl salicylate is not present in the plant until formed by enzymatic action from a glycoside within the leaves as they are macerated in warm water. Oil of wintergreen is also manufactured from some species of birch, but these deciduous trees are not called wintergreens. Spiraea plants also contain methyl salicylate in large amounts and are used similarly to wintergreen. Wintergreen has a strong "minty" odor and flavor; however, the Gaultheria-genus plants are not true mints, which belong to the genus Mentha. Wintergreen also is used in some perfumery applications and as a flavoring agent for toothpaste, chewing gum, soft drinks, confectionery, Listerine, and mint flavorings. Wintergreen is used for rust removal and degreasing of machinery and is particularly effective for breaking through sea water corrosion.
2,4-Dinitrophenol (2,4-DNP or simply DNP) is an organic compound with the formula HOC6H3(NO2)2. It occurs as yellow crystals or platelets. It has been used in explosives manufacturing and as a pesticide and herbicide. In humans, DNP causes dose-dependent mitochondrial uncoupling, causing the rapid loss of ATP as heat and leading to uncontrolled hyperthermia—up to 44 °C (111 °F)—and death in case of overdose. Researchers noticed its effect on raising the basal metabolic rate in accidental exposure and developed it as one of the first weight loss drugs in the early twentieth century. DNP was banned from human use by the end of the 1930s due to its risk of death and toxic side effects. DNP continues to be used after its ban and experienced a resurgence in popularity after it became available on the Internet.
Sources: en.wikipedia.org
Chiral column chromatography is a variant of column chromatography that is employed for the separation of chiral compounds, i.e. enantiomers, in mixtures such as racemates or related compounds. The chiral stationary phase (CSP) is made of a support, usually silica based, on which a chiral reagent or a macromolecule with numerous chiral centers is bonded or immobilized. The chiral stationary phase can be prepared by attaching a chiral compound to the surface of an achiral support such as silica gel. For example, one class of the most commonly used chiral stationary phases both in liquid chromatography and supercritical fluid chromatography is based on oligosaccharides such as amylose, cellulose, or cyclodextrin (in particular with β-cyclodextrin, a seven sugar ring molecule) immobilized on silica gel. The principle can be also applied to the fabrication of Monolithic HPLC columns or Gas Chromatography columns. or Supercritical Fluid Chromatography columns.
== Diagnostic use == Factor XIII levels are not measured routinely, but may be considered in patients with an unexplained bleeding tendency. As the enzyme is quite specific for monocytes and macrophages, determination of the presence of factor XIII may be used to identify and classify malignant diseases involving these cells.
Other effects have been reported to include confusion, lethargy, laziness, sleepiness, lightheadedness, feeling faintish and actual fainting, brief but repeated periods of amnesia, fear of psychosis, pupil dilation, paresthesia, nausea, vomiting, abdominal cramps, diarrhea, and muscle tremors, among others. The drug was described as a "seminal" or "archetypal" psychedelic in PiHKAL.
=== BsAbs on the market === Several bispecific antibodies are presently in clinical use. Blinatumomab, which targets CD19 and CD3, is used in the treatment of Philadelphia chromosome negative B cell acute lymphoblastic leukemia (ALL). Emicizumab, which targets clotting factors IXa and X, is used in the treatment of hemophilia A. Catumaxomab was withdrawn from the European market in 2017 for commercial reasons. Amivantamab, which targets epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Teclistamab, which targets CD3 and B-cell maturation antigen (BCMA), is used in the treatment of multiple myeloma, and zenocutuzumab.
Datasets for Ethiopia and Zimbabwe reported undernutrition rates between 1.5 and 2 times higher in men than in women; however, in India and Pakistan, datasets rates of undernutrition were 1.5–2 times higher in women than in men. Intra-country variation also occurs, with frequent high gaps between regional undernutrition rates. Gender inequality in nutrition in some countries such as India is present in all stages of life. Studies on nutrition concerning gender bias within households look at patterns of food allocation, and one study from 2003 suggested that women often receive a lower share of food requirements than men. Gender discrimination, gender roles, and social norms affecting women can lead to early marriage and childbearing, close birth spacing, and undernutrition, all of which contribute to malnourished mothers. Within the household, there may be differences in levels of malnutrition between men and women, and these differences have been shown to vary significantly from one region to another, with problem areas showing relative deprivation of women. Samples of 1000 women in India in 2008 demonstrated that malnutrition in women is associated with poverty, lack of development and awareness, and illiteracy. The same study showed that gender discrimination in households can prevent a woman's access to sufficient food and healthcare. How socialization affects the health of women in Bangladesh, Najma Rivzi explains in an article about a research program on this topic.
Sources: en.wikipedia.org
A record in the form of proof of baptisms shall be made, containing the time and hour of birth. An extract from this register may be used to prove the age of majority or minority and will serve as full legal evidence for this purpose. Before this legal requirement, fifteen Parisian parishes already kept baptismal registers, three kept marriage registers, and one kept burial registers. Presided over by Pope Paul III from 1545 to 1563, the Council of Trent also required priests to keep a register of baptisms performed in their parish. The names of godparents had to be included to prevent marriages between people linked by spiritual kinship (e.g., a godfather and his goddaughter could not marry). The council also mandated that marriages, freely contracted before a priest and two or three witnesses, be preceded by the publication of banns and recorded in a designated register. It also advocated for the union of children without requiring parental consent. In May 1579, the Ordinance of Blois extended the obligation to keep marriage and burial registers throughout France. The Ordinance of Saint-Germain-en-Laye of April 1667, known as the "Code Louis," required these registers to be kept in duplicate: the first copy (the minute) remained in the parish, while the duplicate (the grosse) was deposited at the court registry. In Paris, the Châtelet registry preserved the second copy, with the oldest dating back to 1668. By 1790, the capital had around fifty parishes.
==== Other sulfur compounds ==== Brassica species contain glucosinolates, which are sulfur-containing secondary compounds. Glucosinolates are composed of a β-thioglucose moiety, a sulfonated oxime and a side chain. The synthesis of glucosinolates starts with the oxidation of the parent amino acid to an aldoxime, followed by the addition of a thiol group (through conjugation with glutathione) to produce thiohydroximate. The transfer of a glucose and a sulfate moiety completes the formation of the glucosinolates. The physiological significance of glucosinolates is still ambiguous, though they are considered to function as sink compounds in situations of sulfur excess. Upon tissue disruption glucosinolates are enzymatically degraded by myrosinase and may yield a variety of biologically active products such as isothiocyanates, thiocyanates, nitriles and oxazolidine-2-thiones. The glucosinolate-myrosinase system is assumed to play a role in plant-herbivore and plant-pathogen interactions. Allium species contain γ-glutamylpeptides and alliins (S-alk(en)yl cysteine sulfoxides). The content of these sulfur-containing secondary compounds strongly depends on stage of development of the plant, temperature, water availability and the level of nitrogen and sulfur nutrition. In onion bulbs their content may account for up to 80% of the organic sulfur fraction. It is assumed that alliins are predominantly synthesized in the leaves, from where they are subsequently transferred to the attached bulb scale.
Cyclophosphamide is a common cytotoxic drug used in this manner and is often used in conjunction with total body irradiation. Chemotherapeutic drugs may be used at high doses to permanently remove the recipient's bone marrow cells (myeloablative conditioning) or at lower doses that will prevent permanent bone marrow loss (non-myeloablative and reduced intensity conditioning). When used in non-cancer setting, the treatment is still called "chemotherapy", and is often done in the same treatment centers used for people with cancer.
=== Partial vacuum method (ultra sniffer test) === In contrast to the Helium charged vacuum test, the partial vacuum method, the ultra sniffer test gas method (UST-method) uses a partial vacuum effect, so that gas tightness of the test sample can be detected at normal pressure with the same sensitivity as the helium charged vacuum test with helium gas helium. The method has a sensitivity of 10−12 Pa·m3·s−1. Similar to the classical Helium charged sniffer test the test sample is enclosed in a bag, but in contrast to the classic method, the bag is exposed with a helium-free gas, so that the helium concentration inside the bag can reduced from 5·10−7 to 10−12 Pa·m3·s−1. This sensitivity corresponds to a theoretical gas loss of 1 cm3 in 3000 years. The UST method can be used very economically for the ad hoc testing of test samples. The test system can be set up easily, with normal pneumatic items, such as valves and plastic hoses. For the embedding of the test samples, a simple plastic bag is sufficient. The UST method was also used for the leak testing of component of the fusion experiment Wendelstein 7-X in Germany.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.